Author

D. Behrens

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

A. Scarpa· 2 shared J. T. Siveke· 2 shared R. T. Lawlor· 2 shared B. Horsthemke· 1 shared B. Sitek· 1 shared C. Carbone· 1 shared C. Luchini· 1 shared C. Neander· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Scarpa

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Differential Activity of MAPK signalling Defines Fibroblast Subtypes in Pancreatic Cancer

L. Veghini, D. Pasini, P. Delfino, V. Corbo, E. Fiorini, F. Lupo, M. Bevere, C. Luchini, R. T. Lawlor, A. Scarpa, P. F.-Y. Cheung, J. T. Siveke, C. Vicentini, D. Filippini, S. L. D'Agosto, , R. Fang

This study identifies MAPK signalling as defining fibroblast subtypes in pancreatic cancer, linking MAPKhigh CAFs to poor prognosis and immune evasion.

bioRxiv · Oct 30, 2023Cancer Biology

Epigenetic plasticity via adaptive DNA hypermethylation and clonal expansion underlie resistance to oncogenic pathway inhibition in pancreatic cancer

L. K. Godfrey, J. Forster, S.-T. Liffers, C. Schroeder, J. Koester, L. Henschel, K. U. Ludwig, M. Trajkovic-Arsic, D. Behrens, A. Scarpa, R. T. Lawlor, K. E. Witzke, B. Sitek, S. A. Johnsen, S. Rahmann, , J. T. Siveke

This study identifies adaptive DNA methylation changes and clonal expansion as mechanisms of resistance to MEKi in PDAC, showing reversibility upon drug withdrawal.

bioRxiv · May 20, 2022 · PreprintCancer Biology